Background Meropenem exhibits time-dependent antimicrobial activity and prolonged
infusion (PI)(extended infusion or continuous infusion, EI or CI) of meropenem can better …

Introduction: The pharmacokinetic/pharmacodynamic index determining β-lactam activity is
the percentage of the dosing interval (% T) during which their free serum concentration …

Objectives To evaluate the association between early and cumulative beta-lactam
pharmacokinetic/pharmacodynamic (PK/PD) parameters and therapy outcomes in …

Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill
patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to …

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are the
most common intensive care unit (ICU) infections. We aimed to evaluate the association of …

Abstract Background Several population pharmacokinetic (PopPK) models for meropenem
dosing in ICU patients are available. It is not known to what extent these models can predict …

Background Meropenem plasma concentration above a pathogen's MIC over the whole
dosing interval (100% ƒ T> MIC) is a determinant of outcome in severe infections. Significant …

We assessed the population pharmacokinetics of high-dose continuous-infusion (HDCI)
meropenem in a cohort of patients with Klebsiella pneumoniae carbapenemase (KPC) …

Data of developmental pharmacokinetics (PK) of meropenem in critically ill infants and
children with severe infections are limited. We assessed the population PK and defined the …

Abstract Background and Objectives Meropenem is frequently used for the treatment of
severe bacterial infections in critically ill patients. Because critically ill patients are more …